Is This Dividend Growth Stock a Buy?
Economic concerns ranging from elevated inflation to interest rate hikes have heavily weighed on financial markets this year. This explains why the S&P 500 index has dropped over 17% so far in 2022.
But many stocks have outperformed the index during this time, especially in healthcare. Down just 11% to this point in the year, Stryker (NYSE: SYK) fits into this category. This raises the following two questions: Can the stock's market-beating performance continue? And is Stryker a buy?
Let's dive into the company's fundamentals and valuation to get answers to these questions.
Source Fool.com